Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Ann Diagn Pathol. 2020 Aug;47:151556. doi: 10.1016/j.anndiagpath.2020.151556. Epub 2020 Jun 20.
Oncotype Dx (ODx) recurrence score (RS) is used in early breast cancer to guide the use of adjuvant therapy. In addition to RS the test produces results of reverse transcriptase-polymerase chain reaction (RT-PCR) of Estrogen receptors (ER), Progesterone receptors (PgR) and Human epidermal growth factor receptor 2 (HER2-neu). Our goal was to determine the correlation between immunohistochemistry (IHC) and RT-PCR testing of ER, PgR and HER2-neu and to correlate the results of ODx RS with tumors' grade, age and PgR status. 113 patients with ER+, HER2-neu- breast cancers that underwent ODx testing were analyzed for receptors correlation and concordance rates by the 2 methods. A total of 104 patients had ER+/PgR+ tumors and 9 patients had ER+/PgR- tumors by IHC, the average RS were 17.5 ± 9.1 and 31.2 ± 8.7 (P < 0.001) respectively. The Spearman correlation coefficient between IHC and ODx results were 0.5 (95% CI 0.34-0.62) for ER and 0.78 (95% CI 0.7-0.84) for PgR. The concordance rate between IHC and ODx was 98.2% for ER, 89.4%.for PgR and 99.1% for HER2-neu. Most of the discordant cases (9 out of 13) were low positive (1-10%) by IHC and negative by RT-PCR. In addition higher tumor grade was associated with a higher ODx RS. Our data show that the IHC results were highly concordant with RT-PCR for ER, PgR and Her2-neu. In addition low positive (1-10%) ER/PgR might indicate a real negative status. Our study shows that ER+/PgR- breast cancers are associated with a significantly higher ODx RS.
Oncotype DX（ODx）复发评分（RS）用于早期乳腺癌以指导辅助治疗的应用。除了 RS，该测试还产生雌激素受体（ER）、孕激素受体（PgR）和人表皮生长因子受体 2（HER2-neu）逆转录酶-聚合酶链反应（RT-PCR）的结果。我们的目标是确定 ER、PgR 和 HER2-neu 的免疫组织化学（IHC）和 RT-PCR 检测之间的相关性，并将 ODx RS 的结果与肿瘤的分级、年龄和 PgR 状态相关联。分析了 113 例接受 ODx 检测的 ER+、HER2-neu-乳腺癌患者，以比较两种方法的受体相关性和一致性率。通过 IHC，共有 104 例患者为 ER+/PgR+肿瘤，9 例患者为 ER+/PgR-肿瘤，平均 RS 分别为 17.5±9.1 和 31.2±8.7（P<0.001）。IHC 与 ODx 结果的 Spearman 相关系数分别为 ER 0.5（95%置信区间 0.34-0.62）和 PgR 0.78（95%置信区间 0.7-0.84）。ER 的 IHC 与 ODx 一致性率为 98.2%，PgR 为 89.4%，HER2-neu 为 99.1%。大多数不一致病例（13 例中有 9 例）IHC 为低阳性（1-10%），而 RT-PCR 为阴性。此外，肿瘤分级越高，ODx RS 越高。我们的数据表明，IHC 结果与 ER、PgR 和 Her2-neu 的 RT-PCR 高度一致。此外，低阳性（1-10%）ER/PgR 可能表明真正的阴性状态。我们的研究表明，ER+/PgR-乳腺癌与 ODx RS 显著升高相关。
